| Literature DB >> 10486693 |
F W Verheugt1, R C Becker, M E Bertrand, C Bode, J H Chesebro, J G Cleland, R Conti, W S Hillis, W Klein, A Maseri, A G Turpie, L Wallentin, D D Waters.
Abstract
Unstable coronary artery disease continues to pose a major challenge to clinicians. The advent of new therapies, such as percutaneous transluminal coronary angioplasty, low-molecular-weight heparins, and glycoprotein IIb/IIIa inhibitors, provides new management options for this indication but also raises new questions with regard to optimal management. Prospective randomized trials with well-defined, long-term outcome measures and a means of identifying which patients will derive most benefit from each treatment, together with a means of rapid and clear dissemination of study results and implications, are required in order to advance the management of unstable coronary artery disease.Entities:
Mesh:
Substances:
Year: 1999 PMID: 10486693 PMCID: PMC6655658 DOI: 10.1002/clc.4960220903
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882